MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data

MoonLake's stock is under pressure as investors await the primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in active psoriatic arthritis.

The readout is expected mid-2026, as consistently guided by MoonLake.

Sonelokimab is being investigated for certain patients with active psoriatic arthritis.

The trial's outcome could impact MoonLake's market position and stock performance.